Rupitasertib

N/A

Report date: 2024/01/29 15:08:43

NME

Base Information

Drug NameRupitasertib

Drug Alias NameM-2698MSC-2363318ADIACC-3010DIACC3010

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitors70-kDa ribosomal protein S6 kinases inhibitorsSerine/threonine-protein kinase AKT3 inhibitors

Targets70-kDa ribosomal protein S6 kinasesSerine/threonine-protein kinase AKT1Serine/threonine-protein kinase AKT3

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEmd Serono Inc

China Registration ClassN/A

Develop Information

Active CompaniesEvexta Bio SA

Inactive CompaniesEmd Serono Inc

Active IndicationsStomach NeoplasmsBreast NeoplasmsGlioblastoma

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A